Variational AI

Variational AI

A generative AI platform for designing small molecules in drug discovery

Officially listed
English
Paid
AI药物研发
0favorites
1views
Promote this tool
Variational AI screenshot

Tool details

Traditional drug discovery starts by screening libraries, which means circling chemical space others have already walked. Variational AI's Enki changes the starting point: no library, just molecules generated to the properties you ask for.

Core Capabilities

  • Generate to a TPP: feed in the target product profile — targets, physicochemical properties — and get novel structures that meet the constraints.
  • 873 pre-trained targets: spanning kinases, GPCRs, proteases and ion channels, so difficult targets still have a starting point.
  • Synthesis built in: the vendor claims a 90% synthetic success rate and about 100 lead-like compounds per run, ready to order.
  • Multi-objective optimisation: balances more than 50 properties at once, covering potency, selectivity, ADMET and synthetic feasibility.
  • Scaffold-constrained optimisation: lock the core scaffold and change only the periphery, which suits lead optimisation of an existing series.
  • New modalities: Enki 4 extends to degraders, PROTACs, molecular glues and novel payloads for antibody-drug conjugates.

Use Cases Pharma and biotech teams that have chemistry and biology depth but lack novel starting points. Sparse data, neglected targets and programmes where library screening returns nothing are its natural territory. It does not run experiments for you: generated molecules still go to synthesis and assay, so treat it as a way to move trial and error into the computer.

What Sets It Apart Competitors compete on compute for faster screening; Enki competes on whether it can propose molecules that are not in any library. The vendor says it needs far less compute and data than foundation models in other domains, which matters more to budget-constrained teams.

Editor's Take Founded in 2019 in Vancouver, it closed a seed extension in 2025 with a Merck fund participating, and the Merck and Rakovina collaborations are the strongest endorsements so far. But every core performance figure is vendor-reported, with no independent benchmark and no peer-reviewed paper. This is a tool for professional chemistry teams, not a toy for individuals.

Pricing

Custom pricingQuote-based (project-based, no public list price)
Enki platform access
Custom (project-based)

Scoped by project duration and number of targets

Partnered discovery programme
Custom (partnered program)

Run jointly with pharma partners, terms negotiated per programme

Additional notes

No pricing page on the site, only an ACCESS ENKI business entry point; no self-serve trial and no public API documentation.

FAQ

No. It is quoted per project with no public price list and no self-serve trial; you reach the team through the ACCESS ENKI entry point.

User reviews

User Reviews

No reviews yet

No one has reviewed this tool yet